ZBIO (Zenas BioPharma) ROCE %: -59.04% (As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $25.79
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma ROCE %?

Zenas BioPharma ZBIO +4.86% 12 ROCE % is -59.04% as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zenas BioPharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -59.04%.

Zenas BioPharma  (NAS:ZBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zenas BioPharma ROCE % Related Terms

Zenas BioPharma ROCE % Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma ROCE % Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
-154.69 -58.05 -87.56 -116.93

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.24 -84.14 -74.72 -312.12 -59.04
ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma ROCE % Calculation

Zenas BioPharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-370.489/( ( (369.968 - 57.292) + (383.64 - 62.649) )/ 2 )
=-370.489/( (312.676+320.991)/ 2 )
=-370.489/316.8335
=-116.93 %

Zenas BioPharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-297.424/( ( (383.64 - 62.649) + (747.682 - 61.161) )/ 2 )
=-297.424/( ( 320.991 + 686.521 )/ 2 )
=-297.424/503.756
=-59.04 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -59.04% mean?
Zenas BioPharma (ZBIO) has a ROCE % of -59.04% as of Mar. 2026.
Is Zenas BioPharma's ROCE % too high?
Zenas BioPharma's current ROCE % is -59.04%. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's ROCE % compare to MNKD and OLMA?
Zenas BioPharma's ROCE % of -59.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Zenas BioPharma's current ROCE % is -59.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current ROCE % of -59.04%. The current ROCE % is -59.04%. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current ROCE % is -59.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.79
Price